

Commentary

Global equities retreated for a second month in October (-0.4%) on a resurgence in COVID-19 cases and risk aversion ahead of the US election. Whilst investors continued to exhibit a slight preference for growth over low multiple - or value - stocks, there was a rotation in the market as Tech underperformed and Financials outperformed. Elsewhere, Consumer Discretionary outperformed, whilst Healthcare and Energy lagged.

US equities fell (-0.6%) as the market began to factor in the potential of a Democratic sweep of the House, Senate and the Presidency against a backdrop of continued gridlock on a new fiscal package. Cyclical outperformed on the potential of more aggressive stimulus under a Blue sweep, while the US technology giants retreated despite posting strong earnings. Europe underperformed as new COVID lockdowns in several major countries weighed on the consumer outlook (-3.7%).

Asia broadly outperformed (+3.2%) led by China (+6.9%) as the relaxation of internal COVID restrictions and the unveiling of the central government's 14th Five Year Plan, led to optimism over momentum in its economic recovery.

Elsewhere, US Treasury yields rose sharply on post-election fiscal hopes. Brent Crude continued to fall on continued demand concerns.

Key contributors to performance included:

- Online Services Asia/Emerging Markets (EM) including Tencent, which benefited from recovery in digital advertising and attention on payments

Net performance (%)

	Fund	Benchmark	Difference
1 month	1.8	-0.4	2.2
3 month	4.0	2.3	1.7
Year to date	-3.2	-1.0	-2.2
1 year	0.5	2.9	-2.4
3 year p.a.	4.5	8.7	-4.1
5 year p.a.	8.3	8.5	-0.2
Inception p.a.	8.9	8.9	0.0
Inception	57.8	57.9	-0.1

Past performance is not a reliable indicator of future performance. Returns are quoted in AUD and net of applicable fees, costs and taxes

Performance & risk summary¹

Average net exposure	87.9%
Upside capture ratio	97
Downside capture ratio	83
Portfolio standard deviation	10.8%
Benchmark standard deviation	10.8%
Sharpe ratio	0.83

¹All metrics are based on gross of fee returns in AUD terms. The upside/downside capture ratio is the percentage of benchmark performance captured by the fund during months that the benchmark is up/down. Standard deviation is a measure of risk with a smaller figure indicating lower return volatility. The Sharpe ratio measures returns on a risk adjusted basis with a figure > 1 indicating a higher return than the benchmark for the respective levels of return volatility

Performance contribution² (%)

	1 month
Long	1.9%
Currency	0.0%

² Based on gross returns in AUD


businesses with the Ant Group IPO, and Alibaba which highlighted ventures in retail and food delivery are moving towards profitability.

- Consumer Cyclical Asia/EM, notably KB Financial and HDFC Bank, as both reported strong results highlighting ongoing normalisation of their domestic economies. In particular, recovery has gathered pace in India and HDFC has taken market share.
- EDF (Infrastructure Developed Markets), which revised full year guidance upwards for nuclear generation and benefited from incremental news around imminent regulatory reform and restructuring.
- Tapestry (Consumer Cyclical DM), which delivered a strong result driven by e-commerce and sales in China. Further, initiatives to focus the product offer, increase prices and reduce discounts have begun to bear fruit.

Key detractors to performance included:

- Healthcare cluster including Merck and Sanofi as pharma has been impacted by the potential for adverse drug pricing policies under a potential Democratic clean sweep in the US elections.
- Oil/natural gas cluster including TechnipFMC which reported a better than expected result but failed to revise full year guidance upwards.
- Siemens (Industrials cluster), following a period of strong performance over the prior six months.

Top & bottom sector contribution^{2,4} (%)



⁵ Antipodes classification

Fund facts


Characteristics	
Investment manager	Antipodes Partners
Inception 1 date	1 July 2015
Benchmark	MSCI All Country World Net Index in AUD
Management fee	1.20% p.a.
Performance fee	15% of net return in excess of benchmark
Buy/Sell spread	±0.30%
Minimum investment	AUD \$25,000
Distribution	Annual, 30 June
Asset value	
Fund AUM	\$922m
Strategy AUM	\$2,455m
Unit redemption price	1.0753

Asset allocation³

	Equities - Long	Other - Long
Weight (% NAV)	92.0	-
Count	62	-
Avg. weight	1.5	-
Top 10 (% NAV)	27.9	-
Top 30 (% NAV)	66.4	-

³Call (put) options represented as the current option value (delta adjusted exposure)

Sector exposure^{3,4} (%)




⁴ Antipodes classification

Top 10 equity longs³ (%)

Name	Country	Weight
Électricité de France	France	3.2
Tencent	China/HK	3.1
Ping An Insurance	China/HK	3.1
Facebook	United States	2.9
Alibaba	China/HK	2.9
Microsoft	United States	2.8
Siemens	Germany	2.6
Roche	Switzerland	2.5
KB Financial Group	Korea	2.4
Capital One Financial	United States	2.4

Currency exposure^{3,5} (%)



⁵ Where possible, regions, countries and currencies classified on a look through basis

Regional exposure^{3,4,5} (%)

Region	Long
United States	32.8
Western Europe	22.3
- Eurozone	16.4
- Rest Western Europe	4.1
- United Kingdom	1.9
Developing Asia	21.3
- China/Hong Kong	18.5
- India	2.8
Developed Asia	13.8
- Korea/Taiwan	8.8
- Japan	5.0
Australia	1.8
Total Equities	92.0
Cash	8.0
Totals	100.0

Market cap exposure³ (%)

Band	Weight
Mega (>\$100b)	39.5
Large (>\$25b <\$100b)	29.9
Medium (>\$5b <\$25b)	18.8
Small (<\$5b)	3.8

Investment Manager

- Global pragmatic value manager, long only and long-short
- Structured to reinforce alignment between investors and the investment team
- We attempt to take advantage of the market's tendency for irrational extrapolation, identify investments that offer a high margin of safety and build portfolios with a capital preservation focus

Fund features

- Objective to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years)
- In the absence of finding individual securities that meet minimum risk-return criteria, cash may be held to maximum 25%
- Flexibility to hedge for risk management purposes:
 - Currency exposure of the underlying stock position (net short currency position not permitted)
 - Equity market exposure via exchange traded derivatives (limited to 10% of NAV)
 - Leverage not permitted

Fund Ratings



Further information

☎ 1300 010 311

✉ invest@antipodespartners.com

Australia Head Office

Antipodes Partners Limited
Level 35, 60 Margaret St
Sydney NSW 2000
Australia

UK Office

Antipodes Partners Limited
6th Floor, Nova North
11 Bressenden Place
London SW1E 5BY UK

Disclaimer

Disclaimer The Zenith Investment Partners ("Zenith") Australian Financial Services License No. 226872 rating (assigned November 2018) referred to in this document is limited to "General Advice" (as defined by the Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Zenith usually charges the product issuer, fund manager or a related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessment's and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>. The Lonsec Ratings (assigned March 2019) presented in this document are published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at: <http://www.beyond.lonsec.com.au/research-solutions/our-ratings>.

Pinnacle Fund Services Limited ('PFSL') (ABN 29 082 494 362, AFSL 238371) is the product issuer of the Antipodes Global Fund – Long (ARSN 118 075 764) "the Fund". The issuer is not licensed to provide financial product advice. You should consider the Product Disclosure Statement (PDS) in its entirety before making an investment decision. The current PDS of the Fund can be found on www.antipodespartners.com. Antipodes Partners Limited ('Antipodes') ABN 29 602 042 035, AFSL 481580 is the investment manager of the Fund. Whilst Antipodes and PFSL believe the information contained in this communication is based on reliable information, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, Antipodes and PFSL disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information. Any opinions and forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information at the date of publication and may later change without notice. This communication is for general information only. The information is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. This communication has been prepared without taking account of any person's objectives, financial situation or needs. Past performance is not a reliable indicator of future performance. Options exposure represents the market downside. For put options (typically used to limit potential downside) delta-adjusted exposure is used and for call options (typically used to capture potential upside) exposure is calculated using the current option value. Unless otherwise specified, all amounts are in Australian Dollars (AUD). Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from Antipodes.